STOCK TITAN

Acrivon Therapeutics, Inc. - ACRV STOCK NEWS

Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.

Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company dedicated to developing precision oncology medicines. The company specializes in using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match patients with the oncology medicines most likely to work for them. This groundbreaking approach integrates drug-regulated global proteomics with intact tissue digital imaging to create drug-specific biomarker signatures, known as OncoSignature companion diagnostics, for identifying patient responders.

The company's leading candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2. This drug is currently in a potentially registrational Phase 2 trial and has received Fast Track designation from the FDA for investigating its use as monotherapy for patients with platinum-resistant ovarian or endometrial cancer. The ACR-368 OncoSignature test, which is pending regulatory approval, has shown promising results in preclinical studies and past third-party Phase 2 trials.

Additionally, Acrivon is advancing ACR-2316, a selective dual WEE1/PKMYT1 inhibitor designed using the AP3 platform. This candidate shows superior single-agent activity in preclinical studies compared to benchmark inhibitors. Acrivon plans to submit an IND for ACR-2316 in Q3 2024, with clinical study initiation expected in Q4 2024.

The company's AP3 platform not only aids in drug selection but also in rational drug design and optimization. It's engineered to measure drug effects on the tumor cell protein network, identifying resistance mechanisms and optimal drug combinations.

Recently, Acrivon has made significant strides, including FDA Breakthrough Device designation for its ACR-368 OncoSignature assay and a successful $130 million private placement financing to further fund its innovative pipeline and platform development. Acrivon's focus remains on leveraging its AP3 platform for the development of precision oncology drugs that address significant unmet medical needs, aiming to improve treatment outcomes for cancer patients worldwide.

For more updates and detailed financial information, visit Acrivon's investor relations page.

Rhea-AI Summary
Acrivon Therapeutics, Inc. announced data from two posters presented at the AACR Annual Meeting. ACR-2316, a dual WEE1/PKMYT1 inhibitor, showed potent anticancer activity in preclinical studies. AP3 profiling identified ULDG as a sensitizer for resistant ovarian cancer cells to ACR-368, a CHK1/2 inhibitor. Acrivon's precision proteomics-based approach in drug discovery and development was highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
none
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced a securities purchase agreement to issue 8,235,000 shares of common stock and pre-funded warrants, expecting gross proceeds of $130 million. The financing, led by new investors, will support the advancement of their lead clinical asset, ACR-368, and other pipeline programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
62.77%
Tags
none
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. reported financial results for Q4 and full year 2023, highlighting progress in clinical trials for ACR-368 and ACR-2316. The company remains on track to present more mature clinical data in 2024 and has upcoming milestones for 2025. Recent highlights include advancements in IND-enabling studies for ACR-2316 and presentations at the AACR Annual Meeting. Financially, the company reported a net loss of $19.3 million for Q4 2023 and $60.4 million for the full year, with increased R&D and administrative expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.6%
Tags
Rhea-AI Summary
Acrivon Therapeutics, Inc. announces the presentation of data at the AACR Annual Meeting for their novel dual WEE1 and PKMYT1 inhibitor, ACR-2316, developed using AP3. The company's CEO highlights the platform's ability to overcome drug resistance and present a rational combination treatment for their lead asset, ACR-368.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced the appointment of Dr. Santhosh Palani, a seasoned healthcare investor and former drug developer, to its board of directors. Dr. Palani's expertise in biotechnology investments and drug development will enhance Acrivon's precision medicine platform, AP3, which aims to match oncology medicines to patients based on proteomics. His background at PFM Health Sciences and NEA brings valuable experience to Acrivon's innovative approach in oncology and potential expansion into other therapeutic areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.4%
Tags
management
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced its participation in a panel discussion at the TD Cowen 44th Annual Health Care Conference. The company is focused on developing precision oncology medicines using its proprietary platform, AP3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.07%
Tags
conferences
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D., to its board of directors. Dr. Magovčević-Liebisch brings over 25 years of experience in global business, R&D operations, partnering activities, commercialization, and regulatory, legal, and IP strategies. She has held pivotal roles at Vigil Neuroscience, Inc., Ipsen, Teva Pharmaceutical Industries Ltd., and Dyax. Her expertise will benefit Acrivon as they advance their pipeline of novel compounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
management
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced its participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company is developing precision oncology medicines using its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The company's president and CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on February 13, 2024, at 2:40 p.m. ET. The live webcast can be accessed on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
conferences
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced the approval of an equity award under its 2023 Inducement Plan to one employee in the form of stock options. The employee received options to purchase 99,300 shares of Acrivon common stock, with vesting conditions and installments. The grant was approved by Acrivon’s Board of Directors, as required by Nasdaq Rule 5635(c)(4), and was granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.31%
Tags
none
Rhea-AI Summary
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) announced that its president and CEO, Peter Blume-Jensen, M.D., Ph.D., will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference. Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The webcast will be available on the company's website with a replay option for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.63%
Tags
conferences

FAQ

What is the current stock price of Acrivon Therapeutics (ACRV)?

The current stock price of Acrivon Therapeutics (ACRV) is $7.845 as of November 4, 2024.

What is the market cap of Acrivon Therapeutics (ACRV)?

The market cap of Acrivon Therapeutics (ACRV) is approximately 243.1M.

What does Acrivon Therapeutics specialize in?

Acrivon Therapeutics specializes in developing precision oncology medicines using its proprietary AP3 platform to match patients with the most effective treatments.

What is Acrivon's leading drug candidate?

Acrivon's leading drug candidate is ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2, currently in Phase 2 trials.

What is the Acrivon Predictive Precision Proteomics (AP3) platform?

The AP3 platform integrates drug-regulated global proteomics with intact tissue digital imaging to create drug-specific biomarker signatures, aiding in patient responder identification.

Has Acrivon received any regulatory designations for its drugs?

Yes, Acrivon's ACR-368 has received Fast Track designation from the FDA for treating platinum-resistant ovarian or endometrial cancer.

What recent achievements has Acrivon announced?

Recent achievements include FDA Breakthrough Device designation for the ACR-368 OncoSignature assay and a $130 million private placement financing.

What is the status of Acrivon's ACR-2316 drug candidate?

ACR-2316, a dual WEE1/PKMYT1 inhibitor, is in preclinical development with an IND submission expected in Q3 2024 and clinical studies beginning in Q4 2024.

How does the AP3 platform contribute to drug development?

The AP3 platform helps in measuring drug effects on the tumor cell protein network, identifying resistance mechanisms, and optimizing drug design and combinations.

What is the significance of the ACR-368 OncoSignature test?

The ACR-368 OncoSignature test identifies patients most likely to respond to ACR-368 monotherapy, aiding in personalized treatment plans.

How well-funded is Acrivon for its ongoing and future projects?

Acrivon is well-funded, with recent financing expected to support operations into the second half of 2026, providing flexibility for extended research and development.

Where can investors find more information about Acrivon?

Investors can find more detailed updates and financial information on Acrivon's investor relations page.

Acrivon Therapeutics, Inc.

Nasdaq:ACRV

ACRV Rankings

ACRV Stock Data

243.13M
30.97M
22.39%
75.82%
3.59%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WATERTOWN